SHR1127 / Jiangsu Hengrui Pharma - LARVOL DELTA

Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor (AACR 2024) - "It was worth noting that the clinical PoC of KRAS G12D inhibitor has been preliminarily validated by intravenous administration of HRS-4642 weekly. In addition, SHR1127 demonstrated no off-target toxicity and good safety window. An IND submission for SHR1127 is planned in the first half of 2024."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS